ReviewInternational journal of impotence research2002
Activators of soluble guanylate cyclase for the treatment of male erectile dysfunction.
Review in International journal of impotence research, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 62 citations in OpenAlex.
- Article
- The evolution of small molecule enzyme activators.RSC medicinal chemistry · 2023Review
- Erectile Dysfunction: Treatments, Advances and New Therapeutic Strategies.Brain sciences · 2023Review
- Development and therapeutic applications of nitric oxide releasing materials to treat erectile dysfunction.Future science OA · 2015Article
- Current Diagnosis and Management of Erectile Dysfunction.Current sexual health reports · 2014Article
- Inhibition of reactive gliosis prevents neovascular growth in the mouse model of oxygen-induced retinopathy.PloS one · 2011Article
- In vitro and in vivo studies on the importance of the soluble guanylyl cyclase α1 subunit in penile erection.World journal of urology · 2010Article
- The future is today: emerging drugs for the treatment of erectile dysfunction.Expert opinion on emerging drugs · 2010Review
- A Review of the Pathophysiology and Novel Treatments for Erectile Dysfunction.Advances in pharmacological sciences · 2010Article
- Review
- The role of nitric oxide in erectile dysfunction: implications for medical therapy.Journal of clinical hypertension (Greenwich, Conn.) · 2006Review
- In vitro models: research in physiology and pharmacology of the lower urinary tract.British journal of pharmacology · 2006Review
- Hemodynamic effects of sildenafil citrate (Viagra) on segmental branches of bilateral renal arteries.International urology and nephrology · 2005Article
- A comparative study of sildenafil, NCX-911 and BAY41-2272 on the anococcygeus muscle of diabetic rats.International journal of impotence research · 2004Article
- Novel nitric oxide signaling mechanisms regulate the erectile response.International journal of impotence research · 2004Review
- Activation of dopamine D4 receptors by ABT-724 induces penile erection in rats.Proceedings of the National Academy of Sciences of the United States of America · 2004Article
- [Therapy of erectile dysfunction in 2005].Der Urologe. Ausg. A · 2003Article
- Review
- Chuanxiongzine relaxes isolated corpus cavernosum strips and raises intracavernous pressure in rabbits.International journal of impotence researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Soluble guanylate cyclase (sGC) is an important enzyme in corpus cavernosum smooth muscle cells as it is one of the regulators of the synthesis of cGMP. The efficacy of sildenafil (Viagra) in the treatment of male erectile dysfunction indicates the importance of the cGMP system in the erectile response as the increased levels of cGMP induce relaxation of the corpus cavernosum. sGC is physiologically activated by nitric oxide (NO) during sexual stimulation, and its activity can be pharmacologically enhanced by several NO-donors. Agents like YC-1 can also activate sGC after binding to a novel allosteric site in the enzyme, a site different from the NO binding site. YC-1 can relax rabbit cavernosal tissue and it facilitates penile erection in vivo. This review summarizes the enzymology, biochemistry and pharmacology of this novel allosteric site and its relevance for the regulation of penile function. This type of sGC activators represent a new class of compounds with a different pharmacological profile in comparison to the classical NO-donors and they could be beneficial for the treatment of male erectile dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.